Researchers studied 20 patients who were assigned to 12 weeks of supplemental oxygen for 16 or more hours a day or no oxygen ...

Pulmonary arterial hypertension (PAH) is an increasingly understood disease, with the genetics and pathophysiology mapped out to the extent that new therapies are emerging.1 The epidemiology, however, ...

High blood pressure (hypertension) causes thickening of the blood vessels and hardening of the arteries (arteriosclerosis). A ...

Researchers have discovered four critical genes linked to Pulmonary Arterial Hypertension (PAH), paving the way for ...

Preclinical data had suggested reducing serotonin might improve symptoms of pulmonary arterial hypertension, but new phase 2b ...

One of the key highlights was the discussion of Pulmonary Embolism Response Teams (PERT), addressing controversies in PE management and focusing on personalized, patient-centered care.

The global pulmonary arterial hypertension treatment market is on track to achieve significant growth over the next decade, with a projected valuation of USD 7,224.4 million by 2033. This expansion ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among ...

Exosomes released by mesenchymal stem cells may help reduce vascular remodeling and ease PH symptoms, a rat study showed.

A study was conducted to determine the efficacy of several vasodilators for treatment of persistent pulmonary hypertension in newborns.

The Pulmonary Hypertension Association's "Let Your Light Shine" campaign ... The global PH community is encouraged to participate by advocating for better care and treatment access, volunteering to ...